Dr. Dorritie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave
5TH floor UPMC Cancer Pavillion
Pittsburgh, PA 15232Phone+1 412-692-4724Fax+1 412-647-4486
Summary
- Dr. Kathleen Dorritie is an oncologist in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including Shadyside Campus, UPMC Magee-Womens Hospital, and UPMC Presbyterian. She received her medical degree from SUNY Upstate Medical University and has been in practice 10 years. She specializes in hematologic oncology and is experienced in hematologic malignancies and cellular immunotherapy.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2010 - 2013- UPMC Medical EducationResidency, Internal Medicine, 2007 - 2010
SUNY Upstate Medical UniversityClass of 2007
Certifications & Licensure
PA State Medical License 2007 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Stem Cell Transplant in Patients With Severe Sickle Cell Disease Start of enrollment: 2018 Mar 29
Publications & Presentations
PubMed
- A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.Kevin Quann, Konstantinos Lontos, Alison Sehgal, Anastasios Raptis, Annie Im
Haematologica. 2024-12-01 - Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John Tamaresis, Armin Ghobadi
Journal of Clinical Oncology. 2024-10-20 - Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.Annie Im, Kevin Quann, Mounzer Agha, Anastasios Raptis, Robert L Redner
American Journal of Hematology. 2024-03-01
Press Mentions
BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-cell Non-Hodgkin LymphomaDecember 20th, 2019- The Untold Story of the Longest Persisting CAR-T Cells in CLLMay 20th, 2019
The AMA Does Not Speak for UsDecember 9th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
